The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Retiring at 55 sounds like freedom, but seven years without a paycheck or Social Security creates a funding gap that destroys most portfolios before the first benefit check ever arrives. The yield tier you choose now determines whether you cross that bridge or fall through it.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

Johnson & Johnson (NYSE:JNJ) continues to stand out as a dividend stock for investors who value dependable income and a long track record of growth. In April 2026, the company raised its dividend by 3.1%, bringing the quarterly payment to $1.34, or $5.36 a year. It was the company’s 64th consecutive year of dividend increases, […]

J&J raises 2026 outlook after second-quarter sales rise 6.6% to $25.31 billion.

Johnson & Johnson (NYSE: JNJ) received FDA clearance for its MONARCH QUEST 3 bronchoscopy system, a software update to its robotic assisted bronchoscopy platform. The update introduces AI powered tools for procedure planning and lung nodule segmentation within Johnson & Johnson's MedTech portfolio. The clearance expands Johnson & Johnson's capabilities in minimally invasive diagnostics and treatment in robotic assisted bronchoscopy. New digital ecosystem features are designed to support...

J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.

Colgate-Palmolive Company (NYSE:CL) is often overlooked when investors discuss established dividend stocks. Names such as Coca-Cola, Procter & Gamble, and Johnson & Johnson tend to dominate those conversations. Colgate has a track record that deserves to be mentioned alongside them. It is a Dividend King, with 63 consecutive years of dividend increases and uninterrupted dividend payments […]

While the market chases momentum trades and AI multiples, a small group of blue-chip dividend compounders has quietly raised its payouts for generations and continues doing so in 2026. These five names carry the streaks, the cash flow, and the brand moats to keep rewarding patient investors well into next year.

Generating $210,000 a year in dividends sounds impossible until you break the portfolio into three distinct yield buckets, each with its own risk profile and capital requirement. The math is brutally simple, but most investors build the wrong blend and wonder why their income stagnates.

The MONARCH platform provides flexible, robotically assisted visualisation and airway access for bronchoscopic procedures.

The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group's fastest-growing performers trading at a middle-of-the-pack multiple rather than the group high.

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

The biosimilar drag on Johnson & Johnson stock is shrinking, and the business underneath it is already growing at a double-digit pace.

The yield you chase to replace a salary can quietly destroy the purchasing power you built to protect. Before you settle on a number, understand what the tradeoff between yield and dividend growth actually costs you over a decade.